Pal et al. investigated the therapeutic efficacy of FIS in a concentration range of 5–20 μM for 24 h on three BRAF-mutated cell lines (i.e., A375, SK-MEL-28, RMPI-7951), the SK-MEL-119 NRAS-mutated cell line, and the NRAS-BRAF mutated HS294T cell line, their investigation concluding that BRAF-mutated MM cells show a higher sensitivity to FIS-based therapy. Here, NRAS is linked to Miyoshi myopathy.